Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:26 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mechanism of Masked Hypertension - Intervention
NCT04121299 · University of Alabama at Birmingham · PHASE3 · withdrawn · last registry update 2021-11-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of funding” | – | Registry record, University of Alabama at Birmingham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-31Also stopped (withdrawn): Azidus Brasil, Loratadine + Pseudoephedrine sulfate (NCT01055756)
- 2022-10-21Results posted on the registry: Vanderbilt University Medical Center, a drug against ADRB1 (NCT04076072)
- 2022-10-14Phase 3 first posted: Instituto Nacional de Cardiologia Ignacio Chavez, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID + Empagliflozin 10 MG OD (NCT05580510)
- 2022-09-29Results posted on the registry: VA Office of Research and Development, Carvedilol + Spironolactone (NCT02230891)
- 2022-08-11Phase 3 first posted: Brugmann University Hospital, Ephedrine + Norepinephrine (NCT05497700)
- 2022-07-22Also stopped (suspended): Beijing Chao Yang Hospital, Montelukast (NCT02655562)
- 2022-07-12Results posted on the registry: Memorial Sloan Kettering Cancer Center, Carvedilol (NCT02177175)
- 2022-07-05Results posted on the registry: University Hospitals Cleveland Medical Center, Vasoconstrictor Agents + Additional anesthesia (NCT01866657)
- 2022-07-05Also stopped (terminated): University Hospitals Cleveland Medical Center, Vasoconstrictor Agents + Additional anesthesia (NCT01866657)
- 2022-06-02Results posted on the registry: Northwestern University, Ephedrine + Phenylephrine (NCT00458003)
- 2022-05-27Results posted on the registry: State University of New York at Buffalo, Carvedilol CR + Valsartan (NCT00657241)
- 2022-05-24Also stopped (withdrawn): YingHsuanTai, Dexamethasone 8 mg + Placebo (0.9% sodium chloride) (NCT05016076)
- 2022-04-18Also stopped (terminated): Shahid Beheshti University, a drug against ADRB1 (NCT03454334)
- 2022-03-11Phase 3 first posted: Centre Hospitalier Universitaire, Amiens, Ephedrine + Norepinephrine (NCT05276596)
- 2021-10-29Phase 3 first posted: St. Justine's Hospital, Dexmedetomidine 0.004 MG/ML [Precedex] + Opioids (NCT05099055)
- 2021-10-28Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), Pseudoephedrine hydrochloride + Guaifenesin (NCT00000752)
- 2021-10-22Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRB1 (NCT03511638)
- 2021-10-19Phase 3 first posted: Medical University of Vienna, Landiolol HCl + Placebo (NCT05084118)
- 2021-09-24Also stopped (terminated): West Virginia University, Carvedilol (NCT03861598)
- 2021-08-06Results posted on the registry: Gainesville Eye Associates, a drug against ADRB1 (NCT03856944)
- 2021-07-16Also stopped (withdrawn): The Hospital for Sick Children, Beta Adrenergic Sweat Test (NCT04274413)
- 2021-06-18Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Landiolol (NCT04931225)
- 2021-06-16Results posted on the registry: University of Birmingham, Bisoprolol + Digoxin (NCT02391337)
- 2021-05-27Also stopped (terminated): Shire, FST-201 (dexamethasone 0.1%) Otic Suspension + ciprofloxacin 0.3%, dexamethasone 0.1% (NCT00945802)
- 2021-05-06Also stopped (suspended): University of Cape Town, a drug against ADRB1 (NCT03071653)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision